The abstract is read at the publisher; the summary is JClub's.
RNA vaccination in murine experimental metastases controls non-neuroendocrine SCLC tumors but shows limited survival benefit against neuroendocrine SCLC tumors established in the lung or liver.
- Why it matters: Subtype-specific immune resistance in SCLC limits immunotherapy effectiveness, and the field lacks strategies to overcome weak survival outcomes in neuroendocrine disease.
- What they did: The study used murine experimental metastases models, comparing interferon-induced MHC-I upregulation kinetics across neuroendocrine and non-neuroendocrine tumors, then profiled vaccination-driven inflammation programs with single-nucleus RNA sequencing and chromatin accessibility.
- The result: Adding liver-targeted RNA-encoded cytokines to RNA vaccination markedly prolonged survival of neuroendocrine tumor-bearing mice and increased inflammatory immune activity in the tumor microenvironment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.